International Archives of Allergy and Immunology
Original Paper
Diesel Exhaust Inhalation Enhances Airway Hyperresponsiveness in MiceMiyabara Y. · Ichinose T. · Takano H. · Sagai M.Research Team for Health Effects of Air Pollutants, National Institute for Environmental Studies, Ibaraki, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 02, 1998
Issue release date: June 1998
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Abstract
Background: Repeated intratracheal instillation of diesel exhaust particles and ovalbumin-induced airway hyperresponsiveness and airway inflammation in mice. However, the effects of daily inhalation of diesel exhaust may differ from the effects of direct instillation. Methods: Therefore, mice were exposed to diesel exhaust by inhalation 12 h per day for 3 months. Before the diesel exhaust exposure, ovalbumin was injected intraperitoneally as a sensitization. After 3 weeks of diesel exhaust exposure, these mice were challenged with ovalbumin every 3 week thereafter. Results: Diesel exhaust exposure with antigen challenge induced airway hyperresponsiveness and airway inflammation which was characterized by increased numbers of eosinophils and mast cells in lung tissue. The recruitment of inflammatory cells was accompanied by an increment in goblet cells on bronchial epithelium. Diesel exhaust exposure alone also enhanced airway hyperresponsiveness, but did not induce eosinophilic infiltration and/or an increment in goblet cells. Conclusion: Diesel exhaust inhalation enhanced airway hyperresponsiveness and airway inflammation caused by ovalbumin sensitization in mice.
Related Articles:
References
- Broide DH, Gleich GJ, Cuomo AJ, Coburn DA, Federman EC, Schwartz LB, Wasserman SI: Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol 1991;88:637–648.
- Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P: Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033–1039.
- Drazen JM, Arm JP, Austen KF: Sorting out the cytokines of asthma. J Exp Med 1996;183:1–5.
- Sagai M, Furuyama A, Ichinose T: Biological effects of diesel exhaust particles (DEP). III. Pathogenesis of asthma like symptoms in mice. Free Radic Biol Med 1996;21:199–209.
- Takano H, Yoshikawa T, Ichinose T, Miyabara Y, Imaoka K, Sagai M: Diesel exhaust particles enhance antigen-induced airway inflammation and local cytokine expressions in mice. Am J Respir Crit Care Med 1997;156:36–42.
- Custovic A, Green R, Taggart SC, Smith A, Pickering CA, Chapman MD, Woodcock A: Domestic allergens in public places. II: Dog (Can f1) and cockraoch (Bla g2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings. Clin Exp Allergy 1996;26:1246–1252.
-
Kaneko S, Shimada K, Hirouchi H, Endo A, Kodama M, Shinoda N, Imai T, Kakiguchi K: Nasal allergy and air pollution. Otorhinolaryngology 1980;23:270–279.
- Sagai M, Saito H, Ichinose T, Kodama M, Mori Y: Biological effects of diesel exhaust particles (DEP). I. In vitro production of superoxide and in vivo toxicity in mice. Free Radic Biol Med 1993;14:37–47.
- Sorkness R, Clough JJ, Castleman WL, Lemanske RF: Virus-induced airway obstruction and parasympathetic hyperresponsiveness in adult rats. Am J Respir Crit Care Med 1994;150:28–34.
- Sakaguchi M, Inoue S, Miyazawa H, Tamura S: Measurement of antigen-specific mouse IgE by a fluorometric reverse (IgE-capture) ELISA. J Immunol Methods 1989;116:181–187.
- Tunniciffe WS, Burge PS, Ayres JG: Effect of domestic concentrations of nitrogen dioxide on airway responses to inhaled allergen in asthmatic patients. Lancet 1994;344:1733–1736.
- Devalia JL, Rusznak C, Wang J, Khair OA, Abdelaziz MM, Calderon MA, Davies RJ: Air pollutants and respiratory hypersensitivity. Toxicol Lett 1996;86:169–176.
- Fujimaki H, Saneyoshi K, Shiraishi F, Imai T, Endo T: Inhalation of diesel exhaust enhances antigen-specific IgE antibody production in mice. Toxicology 1997;116:227–233.
- Takafuji S, Suzuki S, Koizumi K, Tadokoro K, Miyamoto T, Ikemori R, Muranaka S: Diesel-exhaust particulates inoculated by the intranasal route have an adjuvant activity for IgE production in mice. J Allergy Clin Immunol 1987;79:639–645.
- Diaz-Sanchez D, Dotson AR, Takenaka H, Saxon A: Diesel exhaust particles induce local IgE production in vivo and alter the pattern of IgE messenger RNA isoforms. J Clin Invest 1994;94:1417–1425.
- Takenaka H, Zhang K, Diaz-Sanchez D, Tsien A, Saxon A: Enhancement human IgE production results from exposure to the aromatic hydrocarbons from diesel exhaust: Direct effects on B-cell IgE production. J Allergy Clin Immunol 1995;95:103–115.
- Tsien A, Diaz-Sanchez D, Ma J, Saxon A: The organic-component of diesel exhaust particles and phenanthrene, a major polyaromatic hydrocarbon constituent, enhances IgE production by IgE secreting EBV-transformed human B cells in vitro. Toxicol Appl Pharmacol 1997;142:256–263.
- Diaz-Sanchez D, Tsien A, Fleming J, Saxon A: Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human in vivo nasal ragweed-specific IgE and skews cytokine production to a helper cell 2-type pattern. J Immunol 1997;158:2406–2413.
- Oettgen HC, Martin TR, Wynshaw-Borls A, Deng C, Drazen JM, Leder P: Active anaphylaxis in IgE-deficient mice. Nature 1994;370:367–370.
- Mehlhop PD, Rijn M, Goldberg AB, Brewer JP, Kurup VP, Martin TR, Oettgen HC: Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA 1997;94:1344–1349.
- Brusselle GG, Kips JC, Tavernier JH, Heyden JG, Cuvelier CA, Pauwels RA, Bluethmann H: Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1994;24:73–80.
- Korsgren M, Erjefalt JS, Korsgren O, Sundler F, Persson CGA: Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice. J Exp Med 1997;185:885–892.
- Hogan SH, Mould A, Kikutani H, Ramsay AJ, Foster PS: Aeroallergen-induced eosinophilic inflammation, lung damage, and airway hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest 1997;99:1329–1339.
- Lefort J, Bachelet CM, Leduc D, Vargafting BB: Effect of antigen provocation of IL-5 transgenic mice on eosinophil mobilization and bronchial hyperresponsiveness. J Allergy Clin Immunol 1996;97:788–799.
- Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, Locksley RM: Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996;183:109–117.
Article / Publication Details
Published online: June 02, 1998
Issue release date: June 1998
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
